{"id":1288,"date":"2008-01-27T15:42:41","date_gmt":"2008-01-27T14:42:41","guid":{"rendered":"https:\/\/lensounds.com\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/"},"modified":"2008-01-27T15:42:41","modified_gmt":"2008-01-27T14:42:41","slug":"clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/","title":{"rendered":"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6"},"content":{"rendered":"

Abstract<\/h2>\n

This study investigated using alpha-particle\u2013emitting 211<\/sup>At attached to monoclonal antibodies for treating recurrent brain tumors. Eighteen patients received injections of labeled antibodies into surgically created resection cavities. Results showed 96.7% \u00b1 3.6% of 211<\/sup>At decays occurred in the SCRC, with minimal systemic exposure and no dose-limiting toxicity. Six patients experienced mild neurologic side effects that resolved quickly. Median survival for all patients was 54 weeks, with promising outcomes suggesting this approach is feasible, safe, and associated with promising antitumor benefit in patients with recurrent malignant brain tumors.<\/p>\n

Publication Information<\/h2>\n

Journal:<\/strong> Journal of Nuclear Medicine<\/p>\n

Volume:<\/strong> 49, Issue 1<\/p>\n

Pages:<\/strong> 30-38<\/p>\n

Publication Date:<\/strong> January 2008<\/p>\n

DOI:<\/strong> 10.2967\/jnumed.107.046938<\/p>\n

Journal Link:<\/strong> https:\/\/jnm.snmjournals.org\/content\/49\/1\/30<\/a><\/p>\n

Authors<\/h2>\n

Michael R. Zalutsky, David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, Roger E. McLendon, Terence Z. Wong, Darell D. Bigner<\/p>\n

Institutional Affiliation:<\/strong> Duke University Medical Center, Durham, North Carolina, USA<\/p>\n

Study Period:<\/strong> April 1998 \u2013 June 2001<\/p>\n","protected":false},"excerpt":{"rendered":"

Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. Journal of Nuclear Medicine 2008;49(1):30-38. DOI: 10.2967\/jnumed.107.046938<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[49],"class_list":["post-1288","science","type-science","status-publish","hentry","science_category-at-211-publications"],"yoast_head":"\nClinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco\" \/>\n<meta property=\"og:description\" content=\"Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. Journal of Nuclear Medicine 2008;49(1):30-38. DOI: 10.2967\/jnumed.107.046938\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\\\/\",\"name\":\"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2008-01-27T14:42:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco","og_description":"Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. Journal of Nuclear Medicine 2008;49(1):30-38. DOI: 10.2967\/jnumed.107.046938","og_url":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/","og_site_name":"Atonco","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/","url":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/","name":"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2008-01-27T14:42:41+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"Clinical Experience with \u03b1-Particle\u2013Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/1288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1288"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=1288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}